Equillium (NASDAQ:EQ) Trading Up 1%

Equillium, Inc. (NASDAQ:EQ – Get Rating) shares rose 1% during trading on Tuesday . The stock traded as high as $1.05 and last traded at $1.02. Approximately 42,255 shares were traded during trading, a decline of 49% from the average daily volume of 82,164 shares. The stock had previously closed at $1.01.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright increased their price objective on Equillium from $15.00 to $20.00 and gave the company a “buy” rating in a report on Tuesday, September 27th.

Equillium Price Performance

The stock has a market capitalization of $35.10 million, a PE ratio of -0.44 and a beta of 1.23. The stock’s 50 day moving average is $1.30 and its two-hundred day moving average is $1.89. The company has a debt-to-equity ratio of 0.16, a quick ratio of 3.13 and a current ratio of 3.13.

Equillium (NASDAQ:EQ – Get Rating) last posted its earnings results on Monday, November 14th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.01). On average, equities analysts anticipate that Equillium, Inc. will post -1.55 EPS for the current fiscal year.

Institutional Investors Weigh In On Equillium

Institutional investors and hedge funds have recently bought and sold shares of the stock. State Street Corp increased its stake in shares of Equillium by 13.2% during the first quarter. State Street Corp now owns 56,220 shares of the company’s stock worth $177,000 after acquiring an additional 6,564 shares during the period. Jane Street Group LLC purchased a new position in shares of Equillium during the first quarter valued at approximately $47,000. Renaissance Technologies LLC purchased a new position in shares of Equillium during the second quarter valued at approximately $34,000. Dimensional Fund Advisors LP purchased a new position in shares of Equillium during the third quarter valued at approximately $43,000. Finally, Capital CS Group LLC purchased a new position in Equillium during the fourth quarter worth approximately $25,000. 37.64% of the stock is owned by hedge funds and other institutional investors.

Equillium Company Profile

(Get Rating)

Equillium, Inc engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D.